Angela A. Thomas*, Lekshmy Satheesh, Arya Chandran and Dr. Sini S. G.


Gout is a prevalent disorder that has experienced a substantial increase in both incidence and frequency in the last 30 years. It is a urate crystal deposition disease caused by underlying hyperuricemia. It has been suggested that food and genetic factors contribute to elevated levels of monosodium. The diagnosis is based on the detection of uric acid crystals in tissues, body fluids, or joints. The objectives of treatment include stopping the acute attack, preventing further episodes, and preventing side effects from urate crystals accumulating in tissues. The focus of this review article will be on the most recent epidemiology, pathogenesis, modern diagnostic techniques, drugs to lower uric acid levels, and non-pharmacological therapy to enhance patient’s quality of life. The two main goals of gout treatment are to reduce serum urate to a level that stops additional urate crystal formation and to relieve the pain associated with an acute gouty episode. Oral Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), oral colchicine, oral corticosteroids are the medications most frequently used for acute attacks. Benzbromarone, Pegloticase, Febuxostat, Probenecid, and Allopurinol are among the frequently used urate-lowering medications. The approved treatments for gout have certain limits, particularly when treating patients with comorbidities. New treatments to treat and prevent gout flare-ups and underlying hyperuricemia have been found as an impact of a better understanding of the pathophysiology of gout. Some of the newer therapy includes Anakinra, Canakinumab, Rilonacept.

Keywords: Gout, Hyperuricemia, Anakinra, Benzbromarone, Xanthine Oxidase Inhibitor, Newer therapy for Gout.

[Full Text Article]   [Download Certificate]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    APRIL 2024 Issue has been successfully launched on 1 APRIL 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction